Podcasts about biomarkers

Alzheimer's is not inevitable—and it may even be optional. In this groundbreaking episode, you'll learn how to prevent, slow, and in some cases reverse cognitive decline using strategies that also enhance brain optimization, metabolism, and longevity. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey is joined by Dr. Dale Bredesen, a world-renowned neurologist and leading Alzheimer's researcher who has published over 240 peer-reviewed papers. Dr. Bredesen has spent decades proving that Alzheimer's is not a one-pathway disease but a network failure driven by inflammation, toxins, and mitochondrial dysfunction. His protocol has helped thousands of patients regain memory, extend healthspan, and reclaim brain performance. Together, they unpack how biohacking tools like fasting, ketosis, supplements, sleep optimization, cold therapy, and functional medicine can rewire neuroplasticity, protect mitochondria, and keep the brain in “connection mode” instead of decline. You'll hear why the pharmaceutical industry resists these solutions, how toxins like Paraquat and mold fuel cognitive decline, and what young people can do right now to bulletproof their brains for life. This episode is essential listening if you care about hacking human performance, upgrading metabolism, or extending longevity. You'll walk away with practical strategies you can use today—whether that means optimizing your mitochondria with nootropics, strengthening resilience with smarter not harder recovery, or fueling your brain with Danger Coffee. You'll Learn: • Why Alzheimer's can begin as early as your 20s and what biomarkers to track • The seven major drivers of Alzheimer's and how to reverse them with biohacking strategies • How APOE4 genetics, toxins, and inflammation accelerate brain aging—and what to do about it • The role of mitochondria, ketosis, and fasting in restoring brain optimization and neuroplasticity • Why prevention is exponentially easier than reversal and the top three actions you should start in your 20s • How to avoid “learned helplessness” in medicine and reclaim control over your brain span and longevity Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting-edge insights in health, performance, neuroscience, supplements, nutrition, hacking, emotional intelligence, and conscious living. Episodes are released every Tuesday, Thursday, and Friday (audio-only) where Dave asks the questions no one else dares, and brings you real tools to become more resilient, aware, and high performing. Keywords: Alzheimer's prevention biohacking, APOE4 genetics risk, mitochondrial dysfunction brain, network insufficiency model, cognitive decline reversal protocol, neuroplasticity longevity strategies, mild cognitive impairment treatment, subjective cognitive impairment biomarkers, ketoflex 12/3 diet, mycotoxins and Alzheimer's, Paraquat Parkinson's risk, mitochondrial transfusion therapy, fasting neuroprotection, ketosis brain optimization, natokinase soft plaque removal, sleep apnea cognitive decline, functional medicine Alzheimer's, hippocampal volume preservation, nootropics cognitive resilience, learned helplessness medicine Thank you to our sponsors! EMR-Tek | Go to https://www.emr-tek.com/DAVE and use code DAVE for 40% off.fatty15 | Go to https://fatty15.com/dave and save an extra $15 when you subscribe with code DAVE. OneSkin | Get 15% off your first purchase at https://oneskin.co/ASPREY with code ASPREY. Resources: • Dale's Website: https://www.apollohealthco.com/dr-bredesen/ • Danger Coffee: https://dangercoffee.com/DAVE15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Trailer 1:10 — Introduction 2:43 — Personal Story 7:52 — APOE4, Genetics, and Drug Development 11:37 — Pharma, Media, and Pushback 17:13 — Prevention, Stages, and Biomarkers 23:34 — Causes and Mechanisms 30:24 — Parkinson's, Toxins, and Mitochondria 37:17 — Longevity, Biohacking, and Protocols 44:11 — AI, Data, and Future Treatments 54:11 — Case Studies and Success Stories 1:03:00 — Detox, Mold, and Environmental Triggers 1:12:00 — Neuroplasticity and Brain Regeneration 1:20:00 — Hormones, Supplements, and Personalized Hacks 1:29:00 — Cortisol, Addison's, and AI Protocols 1:38:00 — Large-Scale Trials and Global Impact 1:45:00 — Final Takeaways See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

Ina Stelzer, Ph.D., explores how the maternal immune system adapts to support a healthy pregnancy and how disruptions can lead to complications like preterm birth. Her lab identifies early immune changes linked to spontaneous preterm birth and investigates the role of the maternal brain in regulating immune responses. Stelzer uses advanced technologies like mass cytometry and spatial proteomics to map immune and molecular changes in pregnancy, integrating these data with transcriptomics and mouse models. Her team studies how antidepressants affect immune signaling during pregnancy and examines the impact of social and behavioral factors. These insights may reveal biomarkers and therapeutic targets for improving maternal and fetal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40773]

This episode of Space Nuts is brought to you with the support of NordVPN. Protect your online privacy and access with our special deal by visiting www.nordvpn.com/spacenuts or use the promo code SPACENUTS at checkout.Cosmic Mysteries: Little Red Dots and Astronomical AchievementsIn this exciting episode of Space Nuts, hosts Heidi Campo and Professor Fred Watson explore the latest discoveries and breakthroughs in astronomy. From the intriguing mystery of the "little red dots" observed by the James Webb Space Telescope to the historic appointment of the first female Astronomer Royal, this episode is packed with cosmic insights and fascinating stories.Episode Highlights:- The Mystery of the Little Red Dots: Fred delves into the enigma surrounding the bright, red galaxies identified by the James Webb Space Telescope. He explains their significance, formation theories, and how they might provide a glimpse into the early universe, dating back nearly 12 billion years.- Celebrating Michelle Doherty: The hosts proudly announce the appointment of Michelle Doherty as the first female Astronomer Royal in over 300 years. Fred highlights her groundbreaking contributions to planetary science and her pivotal role in major NASA missions, including the Cassini mission to Saturn.- Detecting Life on Mars: A groundbreaking new test developed by researchers in the UK shows promise for detecting signs of life on Mars using existing rover technology. Fred discusses how this test could revolutionize our search for extraterrestrial life by analyzing chemical bonds in cell membranes.- SpaceX's Starship Launches: The episode wraps up with an update on SpaceX's ambitious Starship program, discussing the challenges and successes of recent launches. Fred reflects on the engineering feats and the importance of these missions for future lunar exploration.For more Space Nuts, including our continuously updating newsfeed and to listen to all our episodes, visit our website. Follow us on social media at SpaceNutsPod on Facebook, X, YouTube Music Music, Tumblr, Instagram, and TikTok. We love engaging with our community, so be sure to drop us a message or comment on your favorite platform.If you'd like to help support Space Nuts and join our growing family of insiders for commercial-free episodes and more, visit spacenutspodcast.com/aboutStay curious, keep looking up, and join us next time for more stellar insights and cosmic wonders. Until then, clear skies and happy stargazing.Got a question for our Q&A episode? https://spacenutspodcast.com/amaBecome a supporter of this podcast: https://www.spreaker.com/podcast/space-nuts-astronomy-insights-cosmic-discoveries--2631155/support.

Using biomarker testing and APOE genotyping to determine patient eligibility for amyloid-targeting therapies. Credit available for this activity expires: 8/19/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002844?ecd=bdc_podcast_libsyn_mscpedu

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Michael J. Wilkinson, M.D., F.A.C.C., F.N.L.A., explores the science and clinical evidence behind intermittent fasting and its role in promoting cardiometabolic health. He explains how aligning eating patterns with the body's natural circadian rhythms can improve weight, blood pressure, glucose regulation, and other risk factors, especially in individuals with metabolic syndrome or type 2 diabetes. Wilkinson highlights promising results from time-restricted eating studies conducted in collaboration with UC San Diego and the Salk Institute, where narrowing the daily eating window led to improved metabolic markers and potential benefits beyond weight loss. He also outlines practical tips for safely adopting this lifestyle approach and stresses the importance of ongoing research. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40319]

Send us a textCan AI Grade Cancer Better Than Us? The Truth About T-Cell Imaging, Biomarkers & Digital Pathology DisruptionYou think Saturday mornings are for coffee? Try diving into bone marrow morphology, organ donor kidney biopsies, and AI-driven metastasis detection at sunrise. That's how I do it—and you're invited to join.Welcome to another data-packed episode of DigiPath Digest, where we explore the latest frontier in digital pathology and AI. This time, I reviewed some of the most exciting recent abstracts spanning cancer grading, T-cell quantification, and AI agents in oncology decision-making.These studies aren't just fascinating—they're redefining what's possible in diagnostics, especially in under-resourced areas where digital pathology can create game-changing access and efficiency.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode, we explore how nonprofit organizations like LBDA are working alongside industry partners to shape the evolving landscape of dementia biomarkers—bridging scientific innovation with real-world care. Featuring an engaging conversation with Dr. Sudhir Sivakumaran, Dr. Kathleen Poston, and Dr. Dustin Dunham on clinical utility, patient-centered research, and the road to broader adoption of biomarkers in Lewy body dementia, Alzheimer's disease and related disorders. This episode is sponsored by GE HealthCare

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now! Click here to claim credit for this activity: https://bit.ly/3HtOziO Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now! Click here to claim you CE credit for this activity: https://bit.ly/45u106o Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

In this episode, we take a critical look at the longevity movement and explore the most valuable—yet elusive—biomarkers for athletes. Learn more about your ad choices. Visit megaphone.fm/adchoices

Our kidneys filter out waste while retaining substances the body needs, such as electrolytes. Kidney health, which can be assessed with blood and urine biomarker tests, is paramount to overall health. Yet lifestyle, such as the Western diet and other factors, can damage the kidneys, leading to either a slow progression of issues or acute injury. Dr. Rick Johnson and Mike Haney discuss the role of the kidneys, what lifestyle factors affect kidney health, ways to support the kidneys, and what your biomarker results tell you about the function of these crucial organs.Sign Up to Get Your Free Ultimate Guide to Glucose: https://levels.link/wnl

In this conversation, Thoryn Stephens, a leading expert in neurotechnology and the founder of Brain One, discusses the importance of brain fitness and cognitive training in the modern world. He emphasizes the need for platforms that help individuals optimize their brain health through micro habits and behavioral changes. The discussion covers various aspects of brain measurement, the impact of sleep and nutrition, and the challenges posed by digital distractions. Thorne also shares insights into the future of Brain One and its partnerships aimed at enhancing cognitive health.Chapters00:00 Introduction to Neurotechnology and Brain Fitness03:06 The Importance of Cognitive and Physical Training06:12 Brain Measurement and Optimization Techniques09:04 Adaptive Programs and Micro Habits for Brain Health12:02 The Role of Environment and Connection in Cognitive Health14:58 Changing Behavior and Biomarkers through Micro Habits18:02 The Silent Killers of Cognitive Health20:58 Top ROI Habits for Cognitive Longevity22:12 Optimizing Daily Routines for Better Health25:20 Understanding the Core Areas of Health27:43 Addressing Distraction and Digital Overload30:20 Integrating Technology and Holistic Health34:17 Future Innovations and Partnerships in Health

Standard blood tests barely scratch the surface. Ryan Smith shares how TruDiagnostic's TruAge & TruHealth tests use over 1,700 biomarkers from just a drop of blood to measure biological age, hormone health, immunity & more. Go beyond standard labs & start bioharmonizing with cutting-edge precision so you can make decisions that actually impact how you feel & age. Meet our guest Ryan Smith studied Biochemistry at Transylvania University before founding Tailor Made Compounding, which became one of the fastest-growing healthcare companies in the U.S. After exiting in 2020, he launched several ventures, including TruDiagnostic, a CLIA-certified lab specializing in methylation-based diagnostics for longevity & preventive health. TruDiagnostic leads the field with one of the largest private epigenetic databases, over 13,000 patients, & active participation in 30+ clinical research studies. Ryan remains a key figure in advancing functional medicine through innovative health data solutions. Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a database of of all the current best biohacking deals on technology, supplements, systems and more Latest Summits, Conferences, Masterclasses, and Health Optimization Events: join me at the top events around the world FREE Outliyr Nootropics Mini-Course: gain mental clarity, energy, motivation, and focus Key takeaways Biological age gives a clearer picture of health risk than birthdate by showing how your body is actually aging Lifestyle basics like exercise, clean eating, stress reduction & social connection remain top tools for aging well Some biological age tests are more reliable thanks to stronger prediction power & actionable results Longevity interventions can now be ranked using technology that tracks measurable improvements over time Leading tests don't just score your age but give clear next steps to improve healthspan & lifespan DNA methylation data offers biomarker proxies that sometimes outperform traditional blood tests Methylation-based tests bring better precision & consistency than standard lab results affected by daily shifts Immune system strength plays a major role in aging by influencing inflammation & clearing damaged cells Supplement & lifestyle tracking tools now show whether specific changes are actually improving key health markers TruAge tests work well for most while biohackers may benefit more from deeper panels like the TruHealth test Episode Highlights 3:29 What Biological Age Really Tells You 10:12 Inside TruDiagnostic's Testing Framework 11:39 Key Lifestyle & Supplement Insights from the Data 15:10 How to Interpret Your Report & Take Action 30:12 Understanding Your Immune & Metabolic Health 45:29 Practical Application & Future of Epigenetic Testing Links Watch it on YouTube: https://youtu.be/MykPl4fZ3Sc  Full episode show notes: outliyr.com/221 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

Join Dr. Martin in today's episode of The Doctor Is In Podcast.  

In this two-part Episode #176 of the PricePlow Podcast, we explore Gremin, the breakthrough dual polyphenolic ingredient from Zeus Hygia that's revolutionizing sports nutrition recovery. First, we sit down with Dr. Arun Kanth, founder of Zeus Hygia, to dive deep into the science behind this patent-pending combination of curcumin and green coffee extract. Then, we hear from Tyshawn Bryant, founder of Green Regimen, who shares his personal experience testing Gremin and how it led to his company's expansion into India. This episode reveals how Zeus Hygia's proprietary BioFusion Technology solves the notorious bioavailability challenges of curcumin while combining it with chlorogenic acid from green coffee extract, bringing curcumin to the sports nutrition space in proper fashion. With clinical studies showing 60% pain reduction, 21.5% improvement in muscular endurance, and accelerated muscle recovery, Gremin represents a significant advancement in plant-based sports nutrition ingredients. The conversation also explores the entrepreneurial journeys of both founders and the growing collaboration between innovative ingredient companies and passionate brand builders. https://blog.priceplow.com/podcast/zeus-hygia-gremin-arun-kanth-tyshawn-bryant-176 Video: Gremin's Breakthrough Science and Real-World Results https://www.youtube.com/watch?v=Upc5P11Bc-w Detailed Show Notes: The Science and Story Behind Gremin (0:00) – Introduction: Welcome to Zeus Hygia and Gremin (1:15) – Arun's Scientific Background and Journey (4:30) – The Humble Beginnings: Starting Without Backing (6:00) – Choosing Curcumin: The Obvious Starting Point (8:30) – The Sports Nutrition Gap: Identifying Plant-Based Opportunities (10:30) – Patent-Pending Innovation: Combination and Technology (12:45) – The First Company to Combine Green Coffee and Curcumin (14:30) – Clinical Evidence: Two Published Human Studies (16:30) – Comprehensive Performance Testing and Biomarkers (19:30) – Neutral Taste and Formulation Advantages (21:15) – Commercial Success and Market Applications (23:00) – Gummy Applications and Dosing Flexibility (24:30) – Venture Funding Announcement and Future Plans (26:15) – Stadice: The Mango-Based Cognitive Ingredient (28:15) – Connecting with Tyshawn Bryant (29:45) – Zeus Hygia Contact Information and Social Media (33:00) – Part 2: Tyshawn Bryant and the Green Regimen Story (33:45) – Green Regimen's Origin: A Personal Health Crisis (36:00) – From Green Smoothies to Elite Lifestyle Protein (38:30) – The Entrepreneurial Learning Curve (40:30) – Elite Lifestyle Nutrition: The Complete Formula (42:30) – Lessons from the Failed Kids Product (44:00) – The Taste Challenge in Plant-Based Proteins (46:15) – The Secret Weapons: Coconut Water and No Stevia (48:30) – Green Regimen Energy and Focus: Clean Stimulation (50:00) – Actazin: The Kiwi-Based Gut Health Innovation (51:30) – Ben's Kiwi Sleep Discovery (53:15) – The Zeus Hygia Connection: Introducing Gremin (55:45) – The Intensity Chal... Read more on the PricePlow Blog

Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

Send us a textIn this episode, Dr. Kevin White sits down with longtime patient and strategist Chris Dingess for a high-level, human-centered breakdown of the 8 key performance indicators that actually measure aging well — and how to reverse-engineer them using simple, lifestyle-driven inputs.From VO2 Max to visceral fat, insulin sensitivity to sleep quality, this conversation connects the dots between what you measure and what actually matters for long-term health. If you're goal-driven but tired of vague health advice, this episode lays out a clear, empowering path forward — without the hype.The 8 KPIs to listen for:VO2 Max – Cardiorespiratory fitness and enduranceInsulin Sensitivity – Glucose regulation and metabolic healthApoB – A key marker for cardiovascular riskCRP (C-reactive protein) – Inflammation and chronic disease riskBody Composition – Especially visceral fat and lean muscle massBone Density – Structural integrity and long-term mobilitySleep Quality – Cognitive protection and recoveryMovement & Stability – Injury prevention and functional independenceHighlights include:The “business metrics” analogy that reframes your health dataWhy VO2 Max might be the most predictive number for lifespanUnderstanding ApoB, CRP, and DEXA scan results without getting lost in the weedsHow to shift from guessing to tracking — and take action that lastsThis is a deep-dive episode, but one that could truly change how you approach the rest of your life. Prime Health Associates

Dr. Brittany Partain, Associate Director of Clinical Affairs and Physician Education at Exagen has a background in biomedical engineering and a passion for problem-solving, Brittany has carved out a unique role at the intersection of diagnostics, clinical education and biotech innovationIn this episode, we explore why autoimmune diseases like lupus and rheumatoid arthritis are so difficult to diagnose, and how Brittany is helping close that gap through physician education and the use of novel T-cell biomarkers. We also talk about building trust with clinicians, misconceptions around diagnostic tools, and the real challenges of advancing innovation in a field that's historically lagging behind specialities like oncology. Finally, Brittany reflects on her journey as a female leader in MedTech, the importance of collaboration, and why passion matters when navigating a fast-paced, highly regulated industryTimestamps:[00:00:45] Why Autoimmune Diseases Are So Difficult to Diagnose[00:01:55] From Biomedical Engineering to Clinical Affairs[00:04:34] Why Rheumatology Has Lagged Behind[00:07:07] How T-Cell Biomarkers Work and What They Solve[00:09:18] What Autoimmune Diseases Are and How They Present[00:11:05] Common Misconceptions Among Clinicians[00:13:00] How Hospitals and Private Clinics React to New Tools[00:15:07] Building Clinical Trust Through Science[00:18:05] What Most People Don't Know About Autoimmune Disease[00:21:58] Women in Biotech: Breaking Stereotypes and Leading ChangeGet in touch with Brittany - https://www.linkedin.com/in/brittany-d-partain Learn more about Exagen - https://exagen.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Children's Tumor Foundation CEO Annette Bakker discusses what non-profit organizations uniquely bring to clinical research and new financial models sustaining their contribution. Plus, host Deborah Borfitz rounds up the latest news in clinical research: new funding approaches for ALS clinical trials, spatial biology to match patients to trials, a bio map of lung cancer tumor changes, improving diabetes treatment outcomes for patients in China, and more.  Show Notes News Roundup   Fund of Adaptive Royalties Research article in PLOS One TACIT algorithm matching patients to trials Article in Nature Communications Mapping biomarkers linked to treatment resistance Press release on the City of Hope website  Pragmatic diabetes trial in China Paper about China-specific genetic risk score in Diabetologia News of trial launch on the University of Exeter website Cough medicine to slow dementia? Study in JAMA Neurology Beating the EARL hurdles in the UK Study in JAMA Network Open Guest Annette Bakker, Ph.D., CEO of the Children's Tumor Foundation Article in Clinical Research News The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Summary In this truncated replay from a session at the 2025 SF Derm Annual Conference, Dr. Daniel Butler, Dr. Lawrence Eichenfield, Dr. Jason Hawkes, Dr. Shyam Joshi, and Dr. Bob Geng discuss the workup for chronic urticaria, focusing on testing approaches, the role of biomarkers, and insights into immune deficiencies. These panelists share their experiences and guidelines, emphasizing the importance of symptomatic management and the variability of lab results in clinical practice. Takeaways - Initial workup for chronic urticaria often does not require specific testing. - Testing may be justified if standard treatments fail. - International guidelines differ from US guidelines regarding testing. - Biomarkers currently available are not reliable for treatment decisions. - Symptomatic management should be prioritized over extensive testing. - Clinical trials show variability in lab results over time. - Excessive lab testing can lead to confusion and unnecessary anxiety for patients. - Understanding patient history is crucial in diagnosing immune deficiencies. - The role of family history is significant in identifying X-linked conditions. - Collaboration among dermatologists is essential for advancing treatment approaches. Chapters 00:00 - Introduction to Chronic Urticaria Workup 02:47 - Testing Approaches and Guidelines for Chronic Urticaria 05:41 - The Role of Biomarkers in Treatment Decisions 08:16 - Clinical Insights on Immune Deficiencies 11:14 - Variability in Lab Results and Clinical Trials 14:07 - Conclusion and Future Directions in Dermatology

In this mini focus issue of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz explores the evolving landscape of cardiac amyloidosis care. From structural and biomarker findings in the HELIOS-B substudy to broader discussions on access, treatment sequencing, and multidisciplinary care, this episode highlights new momentum in ATTR-CM management. Also covered: a sham-controlled trial on compression therapy for vasovagal syncope and pooled trial data on DOAC use in frail older adults with atrial fibrillation. Fast-moving insights, practical takeaways, and a clear message—amyloidosis is no longer rare and mysterious, but a condition we can monitor, modify, and manage.

In this series, host Catherine Glass speaks with David Cosio about  the complex and often overlooked relationship between anxiety and chronic pain. They explore the neurobiological underpinnings of both conditions, how they influence each other, and what the future of integrated pain management may look like, from AI to psychedelics and beyond.  Timestamps: 1:07 - Background  2:10 - Day to Day  3:21 - Why Pain Management  6:06 - Conversations About Pain  7:54 - Key Neurobiological Mechanisms  9:50 - Genetics  11:02 - Brain Mechanisms  11:32 - Biomarkers 

GSD Presents: Top Global Startups with Todd Feldman From Crisis to Prevention: How AI and Biomarkers Are Rewiring Mental Health July 11th, Friday

The August 2025 recall spotlights four previously released episodes on topics related to dementia diagnosis. The episode begins with Dr. Amy Brodtmann discussing the complexities of diagnosing frontotemporal dementia in clinical practice. Next, Dr. Joseph Therriault delves into the use of plasma biomarkers in diagnosing Alzheimer disease. In the third episode, Dr. Trey Bateman discusses the growing significance of blood-based biomarkers in Alzheimer disease. The episode concludes with Dr. Gregg Day discussing the clinical implications of using plasma biomarkers in real-world patient care. Podcast links:  Frontotemporal Dementia Differential Diagnosis in Clinical Practice Diagnosis of Alzheimer Disease Using Plasma Biomarkers Understanding Blood-Based Biomarkers in Alzheimer Disease Diagnostic Performance of Plasma Biomarkers in the Outpatient Memory Clinic Article links:  Frontotemporal Dementia Differential Diagnosis in Clinical Practice Diagnosis of Alzheimer's Disease Using Plasma Biomarkers Adjusted to Clinical Probability Diagnostic Performance of Plasma p-tau217 and Aβ42/40 Biomarkers in the Outpatient Memory Clinic Disclosures can be found at Neurology.org. 

Osteosarcoma Webinar Series: Amanda Marinoff, MD, a physician-scientist from UCSF will discuss clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group.Despite decades of research, osteosarcoma remains one of the few pediatric cancers without validated molecular biomarkers to guide treatment. The Clinical Biomarkers for Osteosarcoma Stratification (cBOSS) initiative is an international effort to change that. Modeled after a successful framework in Ewing sarcoma, cBOSS convened experts from North America and Europe to systematically evaluate emerging molecular features with the greatest potential for near-term clinical translation. Through a series of structured sessions, the group assessed the biological plausibility, clinical relevance, and implementation feasibility of candidate classifiers across five domains: genomic, transcriptomic, epigenetic, immune, and circulating analytes. This webinar will provide an overview of the cBOSS approach, key findings to date, including the maturity of circulating tumor DNA and MYC amplification as prognostic tools, and the path forward for incorporating molecular stratification into future clinical trials. The goal: to move beyond one-size-fits-all therapy and build a precision medicine framework for osteosarcoma.Dr. Amanda Marinoff is a pediatric oncologist and translational researcher at UCSF, where she focuses on developing molecular biomarkers to improve risk stratification and treatment for children and young adults with osteosarcoma. She co-leads the international cBOSS initiative (Clinical Biomarkers for Osteosarcoma Stratification), which brings together experts across North America and Europe to evaluate and prioritize emerging classifiers for clinical use. Her research aims to bridge the gap between genomic discovery and therapeutic application, advancing precision medicine approaches for patients with high-risk disease. Dr. Marinoff earned her medical degree from Harvard Medical School, completed her pediatrics residency at Boston Children's Hospital, and completed her pediatric hematology/oncology fellowship at UCSF Benioff Children's Hospital. She is an active member of the pediatric solid tumor and early-phase clinical trials groups at UCSF.

Dr. Vignesh Devraj explores the Ayurvedic approach to understanding Kapha dosha imbalance through modern biomarkers like cholesterol, insulin resistance, and immune markers. He explains how to differentiate ojas (healthy kapha) from ama (toxic kapha), and the impact of high kapha on issues like weight gain, fatigue, allergies, and depression. You'll also learn powerful lifestyle tips to bring kapha back into balance using diet, exercise, sweating, and Ayurvedic detox therapies like Nasyam and Panchakarma.For a free abstract of this episode, visit vigneshdevraj.comEpisode HighlightsWhat is Kapha? Etymology and core qualitiesLipid profile: Cholesterol, triglycerides, and HDL/LDL explainedOjas vs. Ama: Good vs. bad kaphaAyurveda's concept of immunity (Vyadhi Kshamatva)Lifestyle and Panchakarma Therapies for Kapha BalanceTimestamps00:00 - 02:40: What is Kapha?02:40 - 03:00: Lipid profile and Kapha Imbalance03:00 - 03:30: Ojas vs. Ama: Good vs. bad kapha03:30 - 07:00: Biomarkers, Symptoms and Diseases 07:00 - 08:47: Lifestyle tips, Circadian rhythm & Panchakarma If you are interested in doing one on one Ayurvedic consultation with Dr Vignesh Devraj, please find the details in this link: https://calendly.com/drvignesh/30-minute-session-with-dr-vignesh-devraj-md-ay-istIf you are economically challenged, please use the form provided to request a free Ayurvedic consultation here. (or copy paste this in your browser: https://docs.google.com/forms/d/e/1FAIpQLSd29nHcrC1RssR-6WAqWCWQWKKJo7nGcEm8ITEl2-ErcnfVEg/viewform )You can also visit us at Sitaram Retreat, for bookings check out: www.sitaramretreat.com BALANCE THE MIGHTY VATA - ONLINE COURSE NOW AVAILABLE What makes Ayurveda unique in its treatment approach is its practical wisdom on the concept of Vata. Vata is responsible for Prana - the life energy, nervous system - the master panel of our body, and our emotions. In Ayurveda, it is mentioned that controlling Vata is the most difficult part of healing and recovery. Recently, I have recorded a workshop on - Balancing The Mighty Vata which has over 6 hrs of content, with notes filled with practical inputs that can be integrated into our life. You can access this at https://drvignesh.teachable.com/For further information about Dr Vignesh Devraj, kindly visit www.vigneshdevraj.com and www.sitaramretreat.com Instagram - @sitarambeachretreat | @vigneshdevrajTwitter - @VigneshDevrajWe truly hope you are enjoying our content. Want to help us shape and grow this show faster? Leave your review and subscribe to the podcast, so you'll never miss out on any new episodes. Thanks for your support.Disclaimer: - The content of the podcast episodes is not intended to be a substitute for professional medical procedures, consultations, diagnosis, or treatment in any manner. We strongly do not recommend using the content of these episodes as medical advice for any medical conditions for you, others, or for treating your patients

Send us a textMost people say they want to live longer. Fewer stop to ask: what does “longer” actually feel like?In this follow-up to last week's conversation, Dr. Matt Kaeberlein sits down again with Dr. Nicki Byrne and Dr. Kevin White — this time for an especially detailed, behind-the-scenes deep dive into the blood work and biomarkers that actually matter for health span.If you've ever wanted to understand labs like ApoB, LP(a), fasting insulin, ferritin, hormone panels, or genetic testing — and how to interpret them like a longevity doc — this one's for you. The team walks through what they measure, what it means, and how they guide real-world decisions using data most doctors never mention.Whether you're a patient, a clinician, or just tired of biohacking buzzwords, this episode is packed with nuance, context, and clarity — so you can finally make sense of what your labs are telling you (and what to do next).

BUFFALO, NY - July 29, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 25, 2025, titled “Comprehensive genomic profiling of over 10,000 advanced solid tumors.” In this study, led by Jean-Paul De La O from Exact Sciences Corporation, researchers analyzed data from over 10,000 solid tumor samples from patients with advanced cancer and found that more than 90 percent contained genetic changes that could guide treatment. This work demonstrates the growing impact of large-scale tumor DNA and RNA testing on patient care. The researchers retrospectively analyzed OncoExTra assay information for 31 types of cancer, including breast, colorectal, prostate, lung, and ovarian cancers. Their analysis revealed that nearly a third of patients had alterations associated with approved drugs for their specific cancer, while another third had changes linked to therapies approved for other cancers. These results show that detailed genetic profiling could expand treatment choices. “Biomarkers associated with on- or off-label FDA-approved therapies were detected in 29.2% and 28.0% of samples, respectively.” Another relevant discovery was that many important mutations occurred at very low levels, which are often missed by simpler tests. By using a broad and highly sensitive approach, the scientists were able to identify these rare mutations. They also reported that 7.5 percent of samples carried gene fusions, unusual genetic events that can drive cancer growth. Such findings can be critical in selecting therapies that specifically target these abnormalities. The study also highlighted the value of RNA sequencing in detecting fusion events that traditional DNA tests might miss. Prostate cancer and certain sarcomas showed particularly high rates of these fusion alterations. This type of information can refine cancer diagnosis and improve therapy planning. In addition, the researchers identified changes in several major cancer-related pathways, including those that control cell growth, DNA repair, and immune system response. Alterations in these pathways can point to newer treatment options, such as immunotherapy or drugs designed to block specific cell signals. Overall, this study shows that comprehensive genomic profiling can guide more personalized cancer care by identifying mutations, gene fusions, and other molecular patterns. Advanced testing methods like the OncoExTra assay reveal treatment opportunities even in advanced cancers, ensuring that subtle but important genetic changes are detected. DOI - https://doi.org/10.18632/oncotarget.28757 Correspondence to - Jean-Paul De La O - jdelao@exactsciences.com Video short - https://www.youtube.com/watch?v=awiRhDfiMTE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28757 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, solid tumors, comprehensive genomic profiling, matched therapy, gene fusions, limit of detection To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Future nutrition should be personalized, with artificial intelligence as a key driver, according to Melissa Snover, founder of Nourished, a UK-based company that makes 3D-printed gummy vitamin and supplement stacks.  She believes the current approach to supplementation and health products is outdated and poorly tailored to individual needs. Snover, registered dietitian, joined us to discuss the burgeoning field of precision nutrition. Nourished uses AI-powered algorithms to create customized nutrient gummies, based on users' lifestyle data and health goals—an approach she says offers a significant leap beyond the traditional "one size fits all" vitamin regime.  PartiQlar supplementsEnhance your wellness journey with PartiQlar supplements. No magic formulas, just pure single ingredients, like NMN, L-Glutathione, Spermidine, Resveratrol, TMG and Quercetin. Get a 15% discount with the code MASTERAGING15 at PartiQlarSupport the showThe Live Long and Master Aging (LLAMA) podcast, a HealthSpan Media LLC production, shares ideas but does not offer medical advice. If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.

The JournalFeed podcast for the week of July 21-25, 2025.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Monday Spoon Feed:Novel blood-based biomarkers, specifically GFAP, UCH-L1, S100B, and NfL, may be well suited for early classification and triage of patients with acute and subacute minor traumatic brain injury.Tuesday Spoon Feed:To reduce hospitalizations of patients with mild to moderate COVID, treat with nirmatrelvir-ritonavir (Paxlovid) or remdesivir. To shorten the duration of COVID symptoms, azithroycin, favipiravir, molnupiravir, umifenovir, or corticosteroids may help, but they are not standard of care.

In this episode of the Root Cause Medicine Podcast, Dr. Kate Kresge welcomes back Dr. Cheryl Burdette—naturopathic physician, educator, and founder of Precision Point Diagnostics—for a deep dive into one of the most evidence-backed biomarker bundles in functional medicine: the Gut, Oxidation & Stress panel. Dr. Burdette explains how ten underutilized but highly predictive biomarkers—including anti-LPS antibodies, zonulin, 8OHdG, F2-isoprostanes, glutathione, and more—can give clinicians a full-body snapshot of inflammation, leaky gut, immune dysregulation, and oxidative stress. She discusses how each marker ties into chronic conditions from cardiovascular disease to autoimmunity to neuroinflammation—and exactly how to intervene when these labs are out of range. This is a must-listen masterclass for any practitioner working with chronic illness, mystery symptoms, or “normal” labs that don't tell the whole story. You'll Hear Them Discuss: - Why LPS antibodies are one of the most predictive markers in medicine today - How oxidative stress contributes to cardiovascular disease, autoimmunity, and brain fog - What 8OHdG, zonulin, secretory IgA, and glutathione tell us about barrier integrity - The surprising links between gut dysfunction and GLP-1, mood, and immune balance - Case studies showing biomarker-guided interventions that worked - How to boost glutathione (and what forms work best) - When to re-test and what lab shifts to look for - Advanced testing for food sensitivity: IgG subclasses, complement, and tolerance vs. reactivity - Natural GLP-1 agonists, bitters, fiber, and bile as part of metabolic healing

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Many traditional doctors completely miss the connection between Lyme disease and your body's detoxification pathways and it's costing people decades of unnecessary suffering. After sitting down for 90 minutes with Dr. Christina Rahm, who beat Lyme at 19 using detox protocols, here's what blew my mind: Lyme isn't just about spiral bacteria hiding in your tissues. The solution isn't more antibiotics; it's supporting your body's natural ability to eliminate the cellular trash that's jamming up your biological machinery. Join the Ultimate Human VIP community and gain exclusive access to Gary Brecka's proven wellness protocols today!: https://bit.ly/4ai0Xwg Connect with Dr. Christina Rahm: Get Dr. Christina Rahm's book, “Cure the Causes: Live the Life You Want, Not the One Prescribed“ here: http://bit.ly/44HNz3E   Listen to "The Dr. Rahm Show" on all your favorite platforms! YouTube: http://bit.ly/4f6mhrg Spotify: http://bit.ly/44Kbqje Apple Podcasts: http://bit.ly/4nZnJQ9   Connect with Dr. Christina Rahm: Website: http://bit.ly/44WKxaB YouTube: http://bit.ly/4eW7eQA Instagram: http://bit.ly/46lLLOR TikTok: http://bit.ly/3UlNLPM Facebook: http://bit.ly/4kO1B8k X.com: http://bit.ly/4kLROQf LinkedIn: http://bit.ly/4kRxm0C Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD A GAME - USE CODE “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GENETIC TEST: ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 02:38 Journey with Lyme Disease 07:42 What is Immuno Fatigue?  14:21 Overcoming Lyme Disease 23:58 Fungal and Bacterial Component from Lyme Disease 30:59 Self-Treatment from Lyme Disease 34:57 Zeolite Definition and Benefits 41:18 Types of Zeolite Products 46:12 Testing and Biomarkers for Metals, Lyme 57:54 P450 System Definition and Biomarkers 1:03:29 Starting a Detoxification Journey 1:10:00 Getting Emotional and Spiritual Toxins Out of Your Life 1:16:44 What is String Theory? 1:18:52 Treatment Regimens for Children 1:24:15 What does it mean to you to be an “Ultimate Human?” 1:25:00 Connect with Dr. Rahm The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Advanced biomarker testing and a personalized 100-day intervention to adjust biological age are at the heart of a new longevity venture called Hundred. The AI-driven platform uses data from wearable technology together with users' medical histories to devise individual health plans.  Billed as a ‘doctor in your pocket,' the goal is to extend quality of life to a vibrant 100 years, through tailored insights and guidance. Hundred's founder, Tyler Smith, is spearheading an effort to redefine how we understand and manage aging. Citing his own startling results from biological age tests, as a catalyst for the venture, he is a passionate advocate for preventative health measures.In this conversation Smith shares his goals for the platform while Live Long host Peter Bowes pledges to try it out for 100 days.  They also discuss the degree to which technology can replace traditional face-to-face medical consultations and address questions about entrusting our health to AI-driven solutions.JOIN HUNDRED NOWOptimize your healthspan and potentially lower your biological age.  Tyler and the team at HUNDRED are offering $75 in credit for add-on tests and supplements from the HUNDRED marketplace when you sign up at https://www.hundred.com/partners/livelongpodcast Live Long host Peter Bowes is also joining HUNDRED to experience and critique the platform's protocols. Will it lead to a healthier and longer life?  Daily updates starting in August, 2025Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the showThe Live Long and Master Aging (LLAMA) podcast, a HealthSpan Media LLC production, shares ideas but does not offer medical advice. If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.

Dr. Trey Bateman talks with Dr. Gregg Day about the study design, findings, and clinical implications of using plasma biomarkers in real-world patient care.  Read the related article in Alzheimer's & Dementia.  Disclosures can be found at Neurology.org.